Lifecore Biomedical Inc

Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q3 2025

Lifecore Biomedical explores strategic alternatives and strengthens supply agreements

Lifecore Biomedical's Q3 2023 performance was steady, with strategic strengths in supply agreements and expertise in pharmaceutical injectable-grade HA. However, challenges from timing shifts and inflationary pressures were evident. The company anticipates increased revenue-generating capacity and sees opportunities in expanded supply agreements.

Lifecore Biomedical explores strategic alternatives amidst revenue decline and debt challenges

Lifecore Biomedical's Q2 2023 performance reflects revenue decline, lower gross profit, and challenges from heavy debt burden. The company's strategic review process, led by Morgan Stanley, aims to maximize shareholder value through potential sales or financing transactions. Despite uncertainties leading to the withdrawal of fiscal outlook, Lifecore maintains a proactive stance in addressing operational and financial challenges.

Lifecore Biomedical strengthens partnerships and capacity for future growth

Lifecore Biomedical navigated challenges in Q3 2023 with a focus on strategic partnerships, capacity investments, and a vision for significant revenue growth in the future.
Despite a decrease in financial metrics for the quarter, Lifecore's strengths in CDMO services, development portfolio, and agreements with Alcon position it for long-term success.
Opportunities for growth lie in expanding HA raw material manufacturing, doubling capacity, and leveraging industry trends for revenue expansion in the coming years.

Lifecore Biomedical reports revenue growth and strategic investments for growth

Lifecore Biomedical's Q4 2023 performance showed revenue growth and strategic investments in capacity expansion. While facing challenges in maintaining gross profit margins, the company's focus on CDMO services and development projects presents growth opportunities. Uncertainties surrounding fiscal year 2024 guidance indicate ongoing strategic review processes and potential impacts on future performance.

Lifecore Biomedical reports robust fiscal 2024 performance amidst flat 2025 outlook

Lifecore Biomedical demonstrated strong financial performance in fiscal 2024 with notable revenue and profit increases. While challenges like divestitures impacted the company, strategic measures such as workforce reduction and growth strategies position Lifecore for future success. Opportunities lie in the potential for continued financial growth and revenue generation through targeted strategies.

Lifecore Biomedical reports revenue growth amidst challenges, eyes sustainable growth

Lifecore Biomedical Inc showcased revenue growth and operational improvements in Q1 2025, despite facing a net loss. The company's focus on customer acquisition, expansion, and financial stability presents opportunities for future growth and enhanced performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Lifecore Biomedical Incorporated Is Being Examined By The Schall Law Firm Urging Investors With Losses To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Lifecore Biomedical Inc Is Under Scrutiny By The Schall Law Firm, Investors With Losses Are Encouraged To Initiate Dialogues

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors With Losses To Start Conversations, Lifecore Biomedical Inc Under Investigation

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encouraging Investors With Losses To Begin Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Has Begun A Probe Into Lifecore Biomedical Inc And Encourages Investors With Losses To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investigation Into Lifecore Biomedical Inc Commenced By The Schall Law Firm Inviting Investors With Losses To Start Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Lifecore Biomedical Inc Under Investigation By The Schall Law Firm Urging Investors With Losses To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Inquiry Into Lifecore Biomedical Inc And Encourages Investors With Losses To Start Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Starts Investigation Into Lifecore Biomedical Inc And Urges Investors With Losses To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Probe Into Lifecore Biomedical Inc And Encourages Investors With Losses To Engage In Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Promotes Contact From Investors With Losses As It Embarks On Examination Of Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investigation Into Lifecore Biomedical Inc Begins By The Schall Law Firm And It Urges Investors With Losses To Start Communication

LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Motivates Investors With Losses To Initiate Interaction As It Commences Inquiry Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors With Losses To Initiate Communication As It Begins Inquiry Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investors With Losses To Begin Contact As It Starts Investigation Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors With Losses To Initiate Contact As It Commences Probe Into Lifecore Biomedical Inc.

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investors With Losses To Establish Communication As It Begins Investigation Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors With Losses To Initiate Contact As It Commences Probe Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors With Losses To Connect As It Initiates Probe Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investors With Losses To Reach Out As It Begins Investigation Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors With Losses To Make Contact As It Initiates Probe Into Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Lifecore Biomedical Inc Is Under Investigation The Schall Law Firm Urges Investors Who Have Incurred Losses To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Lifecore Biomedical Inc Is Being Probed The Schall Law Firm Encourages Investors Who Have Suffered Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Lifecore Biomedical, Inc. Is Being Probed: The Schall Law Firm Encourages Investors Who Have Suffered Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Lifecore Biomedical Inc Stock (LFCR)